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CDon-pump and probably doing something else, and then you even said
that you would probably replace the valve in the inferences.
Would you consider doing a technique similar to what we do for
mitral valve in the tricuspid valve, that is, for instance, use substitute
chordal such as polytetrafluoroethylene or pericardial to extend the
anterior leaflet, or even suture the posterior to the septal commissure
and transform the tricuspid valve into a bicuspid valve in case you
have a tethering effect? Did you analyze those 14% of cases, as you
said, that were not related to the type of the technique? Therefore, you
still have some cases where the tethering effect pulls down the free
edge, and then whatever you do, even downsize, will leave a tricuspid
regurgitation. What would you do in such an instance?
Dr McCarthy. We don’t want to give the message that weThe Journal of Thoraciment. This would be in only very selected patients. For instance, in
patients with Barlow’s disease it is very rare that one would ever
consider replacing the valve. I think that those almost uniformly
could be repaired.
On the other hand, in the increasing population of patients
with cardiomyopathy, in which the leaflets themselves are nor-
mal, the right ventricle is dilated, and the leaflets are tethered,
it appears that not many of the repair techniques accomplish a
very durable repair. Then it may be safer to replace in that
group than to accept recurrent or residual tricuspid regurgita-
tion. But, again, that would be an uncommon decision. The
techniques of bicuspidization, leaflet extension with pericar-
dium, or chorded extension in this population may be worth-have a low threshold for recommending tricuspid valve replace- while, but we do not yet have that data.c and Cardiovascular Surgery ● Volume 127, Number 3 685
